Browse by author
Lookup NU author(s): Dr Frida Ponthan
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Neuroblastoma, the most common extracranial solid tumour in children, may undergo spontaneous differentiation or regression, but the majority of metastatic neuroblastomas have poor prognosis despite intensive treatment. Retinoic acid regulates growth and differentiation of neuroblastoma cells in vitro, and has shown activity against human neuroblastomas in vivo. The retinoid 9-cis RA has been reported to induce apoptosis in vitro, and to inhibit the growth of human neuroblastoma xenografts in vivo. However, at given dosage, the treatment with 9-cis RA caused significant toxic side effects. In the present study we investigated the bioavailability of 9-cis RA in rat. In addition, we compared two different dose schedules using 9-cis RA. We found that a lower dose of 9-cis RA (2 mg day(-1)) was non-toxic, but showed no significant effect on tumour growth. The bioavailability of 9-cis RA in rat was 11% and the elimination half-life (t1/2) was 35 min. Considering the short t1/2, we divided the toxic, but tumour growth effective dose 5 mg day(-1) into 2.5 mg p.o. twice daily. This treatment regimen showed no toxicity but only limited effect on tumour growth. Our results suggest that 9-cis RA may only have limited clinical significance for treatment of children with poor prognosis neuroblastoma.
Author(s): Ponthan FM, Kogner P, Bjellerup P, Klevenvall L, Hassan M
Publication type: Article
Publication status: Published
Journal: British Journal of Cancer
Year: 2001
Volume: 85
Issue: 12
Pages: 2004-2009
ISSN (print): 0007-0920
ISSN (electronic): 1532-1827
URL: http://dx.doi.org/10.1054/bjoc.2001.2186
DOI: 10.1054/bjoc.2001.2186
Notes: Journal Article Research Support, Non-U.S. Gov't Scotland
Altmetrics provided by Altmetric
